Salivary cortisol, dehydroepiandrosteronesulphate (DHEA–S) and testosterone in women with chronic migraine by unknown
Introduction
Chronic migraine (CM) is the most disabling form of
headache in the second edition of the International
Classification of Headache Disorders (ICHD-II) [1]. The
failure of its treatment is often due to a superimposed
medication overuse headache (MOH), a new form of sec-
ondary headache [2, 3], which has been defined as an
interaction between a medication used excessively and a
susceptible patient [1].
Migraine is a disorder affecting a larger proportion of
women than men [4] and neuroendocrine research has
focused mainly on the relationship between CM and
female sexual hormones levels [5, 6]. Although CM is a
frustrating and stressful condition, little information is
available on the adrenal hormones and their regulation
during the disease.
Studies on neuroendocrine patterns are often limited to
plasma samples. The current possibility to determine andro-
gens and adrenocortical hormones (testosterone, cortisol and
dehydroepiandrosterone-sulphate (DHEA-S)) in saliva
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adrenal (HPA) axis activity was
monitored in 20 women with chron-
ic migraine (CM), previously
affected by medication overuse
headache (MOH), in comparison to
healthy women (20 subjects) by
measuring salivary cortisol, testos-
terone, dehydroepiandrosterone-sul-
phate (DHEA-S) levels, and their
ratios, one week after the end of the
MOH rehabilitation procedure. The
participants were instructed how to
collect saliva samples at home, a
procedure that was performed twice
a day (08:00 a.m. and 8:00 p.m.).
Morning and evening levels of cor-
tisol were significantly increased in
CM patients with respect to con-
trols. With regard to the
cortisol/DHEA-S ratio, an inverse
marker of psycho-physical well-
being, CM women showed signifi-
cantly higher values than controls.
Moreover, testosterone/cortisol
ratios (anabolic/catabolic index of
physical performance) were signifi-
cantly lower in CM patients than in
controls. In the present study, CM
appears not to be associated with an
impairment of cortisol and DHEA-
S circadian fluctuation; however,
CM patients present alterations in
HPA axis function that might con-
tribute to metabolic and psycholog-
ical alterations that have also been
associated with CM.
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offers evident advantages in the sample collection, avoiding
the “stress” of blood taking [7–10]. Therefore, this study
investigates the salivary levels of cortisol, testosterone and
DHEA-S in 20 CM women previously affected by MOH, in
comparison with age and body mass index (BMI)-matched
controls. Moreover, the ratios cortisol to DHEA-S and
testosterone to cortisol were calculated, respectively, as gen-
eral markers of well-being and fatigue [11, 12].
Subjects and methods
Patient population
We selected from 4536 outpatients admitted over a 12-month
period (July 2004–June 2005) at the Regional Referral Headache
Centre at S. Andrea University Hospital 58 women patients
affected by CM and MOH.
CM diagnosis fulfilled the 2004 IHS criteria [1] and MOH
the following revision of IHS criteria for 8.2 Medication-overuse
headache [2].
The enrolled patients attended an in-hospital rehabilitation
procedure ranging from five to ten days, to recover from MOH
[3]. Salivary samples were collected at a time when the patients
had been asymptomatic and had not taken any anti-migraine
medication for at least 14 days. None of the selected patients
presented a previous chronic or episodic tension headache histo-
ry. None of these patients had received any immunosuppres-
sive/corticosteroidal drug in the previous six months. The main
haematological and haematochemical parameters of all subjects
were within the normal range for our laboratory. Sixteen of the
36 eligible woman declined to give salivary samples. The
remaining 20 women voluntarily agreed to participate in the
study and gave their informed consent. The selected women, all
non-smokers, were not consumers of any vasoactive drug that
could influence cortisol secretion (i.e., anti-hypertensives, anti-
depressants, thyroid agents, etc.). Twenty female age-matched
healthy women from the hospital staff were enrolled as the con-
trol group. We matched cases and controls for age and BMI.
BMI was considered because it may affect the concentration of
hormone-binding globulins and testosterone [5, 13].
All participants were fully informed concerning the proce-
dure and gave their written consent. The study protocol was
approved by our Institutional Ethic Board and informed written
consent was obtained also from controls. The recommended
principles of the Declaration of Helsinki, September 1989, were
closely observed during this clinical research.
Subject somatic characteristics are summarised in Table 1.
Experimental study design
In order to evaluate the diurnal fluctuation of cortisol and
DHEA-S, the participants were instructed how to collect saliva
samples at home. The samples of saliva were collected twice a
day (8:00 a.m. i.e., within 1 h of awakening, and 8:00 p.m.) for
two weeks after analgesic drug withdrawal. The selected
patients, all triptan abusers, attended the rehabilitation procedure
in the outpatient regime for 5 days. The treatment consisted in
infusion therapy with tiapride, ketorolac, ademetionine sulphate,
reduced glutation, granisteron and ranitidine [14].
The salivary samples were kept in the home refrigerator until
the participants’ return to the laboratory.
Salivary sampling procedure
Samples of saliva were collected by the Salivette (Sarsted, Italy)
sampling device, which allows quick and hygienic saliva recovery
from a polyester wool swab by centrifugation at 3000 rpm for 5 min.
Measurement of cortisol, DHEA-S and testosterone
For each sample, duplicate measurement was performed on
50–100 µl of saliva by means of commercial immunoenzymatic
kits (Diametra, Italy) for direct salivary assay of cortisol, testos-
terone and DHEA-S. Inter-assay coefficient of variation was
<10%, and intra-assay coefficient of variation <7%, with a min-
imum detectable concentration of cortisol of 0.5 ng/ml, of testos-
terone of 5 pg/ml and of DHEA-S of 25 pg/ml.
Statistical procedure
Analysis of variance (ANOVA) was applied, followed by a multi-
ple comparison test: statistical significance was set at p<0.05 [15].
Results
Diurnal fluctuation of salivary cortisol and DHEA-S levels
As shown in Figure 1, the CM group presents significant-
ly higher levels of cortisol compared to controls, both in
the morning and in the evening. All the subjects, CM and
controls, present cortisol levels significantly higher in the
morning compared to evening measures. Figure 2 presents
data on DHEA-S. There are no statistically significant dif-
ferences between CM and control subjects, whereas the
physiological DHEA-S diurnal fluctuation was signifi-
cantly present in both groups.
Table 1 Somatic characteristics of the subjects. Data are shown as
mean value±SEM
Group Age (years) BMI (kg/m2)
Control (n=20) 48.7±3.3 23.2±1.0
Chronic migraine (n=20) 49.6±4.1 23.7±1.9
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Morning salivary testosterone levels
Salivary testosterone was measured in the morning sam-
ples only. No significant differences were recorded
between the control group (46.89±4.17 pg/ml) and the CM
group (47.74±4.96 pg/ml).
Cortisol/DHEA-S ratio
Data on cortisol/DHEA-S ratios, calculated from morning
values, are reported in Figure 3 (upper part). A significant
increase in cortisol to DHEA-S ratios was found in CM
women in comparison with controls.
Testosterone/cortisol ratio
As shown in Figure 3 (lower part), testosterone/cortisol
ratios, calculated from morning values, were significantly
lower in CM patients than in control subjects.
Discussion
Previous studies from our group and others showed that
saliva allows an easy, stress-free means for monitoring
Fig. 1 Morning and evening salivary cortisol levels (mean
value±SEM). Statistical analysis: ANOVA: F-ratio=4,67, p=0.0351;
post-hoc Fisher’s LSD Multiple-Comparison Test: *p<0.05 vs.
morning control value; °p<0.01 vs. respective morning value
Fig. 2 Morning and evening salivary DHEA-S levels (mean
value±SEM). Statistical analysis: ANOVA: F-ratio=0,00,
p=0.9510; post-hoc Fisher’s LSD Multiple-Comparison Test:
°p<0.05 vs. respective morning value
Fig. 3 Upper: cortisol/DHEA-S ratio (mean value±SEM).
Statistical analysis: Student’s t-test: t=2,65, p=0.0067; *p<0.01 vs.
control. Lower: testosterone/cortisol ratio (mean value±SEM).





changes of adrenal function in physiological and patho-
logical conditions [8–11, 16–18].
The cortisol, DHEA-S and testosterone levels, and
accordingly, the cortisol/DHEA-S and testosterone/corti-
sol ratios, obtained from the saliva appear to be more reli-
able measurements because salivary levels reflect better
than those in plasma the hormone serum fraction that is
biologically active [11, 12].
A dysregulation of cortisol secretion pattern has been
associated with different pathologies [16, 19]. This study
reports that CM appears not to be associated with impair-
ment of circadian variation of cortisol and DHEA-S: the
physiological rhythm was maintained in all the subjects,
with morning levels significantly higher than in the
evening.
Levels of cortisol in saliva of CM patients were consis-
tently higher as compared to healthy subjects. This aspect
is of interest, as experimental data suggest that chronic
exposure to high levels of corticosteroids can contribute to
produce neurotoxic effects [19]. Several mechanisms have
been considered to explain corticosteroid-induced neuro-
toxicity, including metabolic vulnerability of neurons due
to oxygen radical generation and impairment of neuronal
defences against neurologic insults [20]; in addition, corti-
sol hypersecretion is regarded as important in the patho-
physiology of major depression [21] and has been associ-
ated with cognitive dysfunction [22] and also with loss of
bone density [23]. A number of potential actions have been
recently postulated for DHEA-S on cognition and well-
being [7]. DHEA-S might moderate the action of gluco-
corticoids and protect neurons from the neurotoxic effects
of glucocorticoids [23]. In this study CM patients had
DHEA-S levels not significantly lower than controls; how-
ever the cortisol to DHEA-S ratio is significantly higher
than controls. A higher cortisol to DHEA-S ratio was asso-
ciated with lower cognitive performances and greater
mood disturbances [7], suggesting that CM is associated
with a negative index of well-being. Moreover, the lower
testosterone to cortisol ratio measured in CM patients in
comparison with controls confirms the presence of tired-
ness, a symptom frequently reported by the CM patients.
Further studies are required to elucidate the possible
clinical relevance of HPA axis dysfunction in CM.
However, it is clearly important that psychopathological
and metabolic factors are controlled in future investiga-
tions on HPA axis function in CM patients, as migraine is
often associated with different disorders, which are often
highlighted as trigger factors of migraine attacks but may
also appear as a reaction to migraine attacks.
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